Congress orders health agencies to review perimenopause hormone testing evidence
H.R. 9077 — Hormone Health Data and Research Act · Filed by Hillary Scholten (D-MI) · Introduced May 29, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the National Institutes of Health to review existing published evidence on how hormone levels vary in women before perimenopause symptoms appear, and directs the U.S. Preventive Services Task Force to review evidence on whether baseline hormone testing before symptoms helps diagnose or manage perimenopause. Both agencies must report their findings and recommendations to Congress within 18 months. The bill funds no new research directly—it mandates a literature review and evidence assessment to inform future clinical guidance.
Why we flagged it
The bill is a straightforward mandate for federal health agencies to conduct a systematic review of published evidence on perimenopause hormone testing and report findings to Congress. It is a transparency and evidence-gathering mechanism, not a regulatory change or appropriation.
What the text implies
- The 18-month timeline may be tight for a comprehensive evidence review; if agencies cannot complete the work, Congress may face pressure to extend deadlines or appropriate additional resources.
- The bill does not mandate that clinical practice change based on findings—it only requires reporting. Implementation of recommendations depends on downstream action by medical societies, insurers, and providers.
- A finding that baseline hormone testing lacks clinical utility could reduce demand for certain diagnostic tests, affecting clinical laboratories and diagnostic companies; conversely, evidence supporting testing could expand the market.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Women with perimenopause gain from evidence-based clinical guidance informed by a systematic review of existing research. The bill creates transparency and accountability by requiring federal health agencies to assess what is known about hormone testing and report to Congress, potentially improving clinical decision-making and reducing unnecessary or ineffective testing.
Named in the bill
National Institutes of Health (NIH), U.S. Department of Health and Human Services (HHS), U.S. Preventive Services Task Force (USPSTF), House Committee on Energy and Commerce, Senate Committee on Health, Education, Labor, and Pensions
Where it stands
- May 29, 2026 — Introduced · Congress.gov: “Introduced in House”
- May 29, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,445 characters) on Jun 8, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress orders health agencies to review perimenopause hormone testing evidence” QuorumCivic. https://share.quorumcivic.app/bill/119/hr9077 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.